- Home
- SGU vs CADL Comparison
SGU vs CADL Comparison
Compare SGU & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- CADL
- Stock Information
- Founded
- SGU 1995
- CADL 1999
- Country
- SGU United States
- CADL United States
- Employees
- SGU N/A
- CADL N/A
- Industry
- SGU Other Specialty Stores
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- CADL Health Care
- Exchange
- SGU Nasdaq
- CADL Nasdaq
- Market Cap
- SGU 388.5M
- CADL 313.5M
- IPO Year
- SGU 1995
- CADL 2021
- Fundamental
- Price
- SGU $11.59
- CADL $4.81
- Analyst Decision
- SGU
- CADL Strong Buy
- Analyst Count
- SGU 0
- CADL 5
- Target Price
- SGU N/A
- CADL $19.80
- AVG Volume (30 Days)
- SGU 39.2K
- CADL 735.7K
- Earning Date
- SGU 08-06-2025
- CADL 08-14-2025
- Dividend Yield
- SGU 6.34%
- CADL N/A
- EPS Growth
- SGU 33.71
- CADL N/A
- EPS
- SGU 1.66
- CADL N/A
- Revenue
- SGU $1,777,057,000.00
- CADL N/A
- Revenue This Year
- SGU N/A
- CADL N/A
- Revenue Next Year
- SGU N/A
- CADL N/A
- P/E Ratio
- SGU $6.97
- CADL N/A
- Revenue Growth
- SGU N/A
- CADL N/A
- 52 Week Low
- SGU $10.84
- CADL $3.79
- 52 Week High
- SGU $13.75
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- SGU 45.54
- CADL 33.41
- Support Level
- SGU $11.51
- CADL $4.81
- Resistance Level
- SGU $11.72
- CADL $5.01
- Average True Range (ATR)
- SGU 0.20
- CADL 0.30
- MACD
- SGU -0.00
- CADL -0.08
- Stochastic Oscillator
- SGU 23.08
- CADL 5.30
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.